News | August 19, 2024
Aptar’s nasal unidose system delivers FDA-approved neffy
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
The robotic surgery program has continually pushed the boundaries of medical technology
Becomes the first rehab & recovery center in east India to earn NABH accreditation
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
The partnership marks a significant milestone in integrating digital health education into medical curricula
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Subscribe To Our Newsletter & Stay Updated
